Published in:
01-12-2015 | Topic Review
The role of emerging therapy in the management of patients with diffuse low grade glioma
Published in: Journal of Neuro-Oncology | Issue 3/2015
Login to get accessAbstract
Question
What is the role of immunotherapy/tumor vaccines in the treatment of low grade gliomas?
Target population
Adult patients with newly diagnosed WHO grade 2 astrocytoma, oligo-astroctyoma, or oligodendroglioma.
Recommendations
There is no evidence to support a recommendation in regards to the efficacy of immunotherapy or tumor vaccines for the treatment of low grade gliomas. It is recommended that patients be enrolled in properly designed clinical trials to assess immunotherapies and tumor vaccines for low grade gliomas.
Question
What is the role of nutrition in the treatment of low grade gliomas?
Target population
Adult patients with newly diagnosed WHO grade 2 astrocytoma, oligo-astroctyoma, or oligodendroglioma.
Recommendations
There was no evidence to support a recommendation in regard to the efficacy of nutritional therapy for the treatment of low grade gliomas. It is recommended that patients be enrolled in properly designed clinical trials to assess the efficacy of nutrition for this target population.
Question
Is there a role for alternative or targeted therapies in the treatment of low grade gliomas?
Target population
Adult patients with newly diagnosed WHO grade 2 astrocytoma, oligo-astroctyoma, or oligodendroglioma.
Recommendation
There was no evidence to support a recommendation in regard to the efficacy of targeted or alternative agents for the treatment of low grade gliomas. It is recommended that patients be enrolled in properly designed clinical trials to assess alternative and targeted therapies for this target population.